The inherent cytotoxicity of melanin precursors: a revision.

The potential cytotoxicity of the melanogenic intermediates DOPA, (L-3,4-dihydroxyphenylalanine) and DHI (5,6-dihydroxyindole) has long been recognized and exploited as a targeting concept in experimental melanoma therapy. In recent years, however, a novel branchpoint in the melanin biosynthetic pathway has been shown to divert the metabolism of DOPAchrome to a carboxylated derivative termed DHICA (DHI-2-carboxylic acid) rather than to DHI. In order to evaluate the biological implications of this regulatory control, we have reexamined the inherent cytotoxicity of DHICA versus DHI on different cell lines. We found that under the usual conditions of the biological assay, the apparent cytotoxicity of the two indoles reflect their instability in the culture medium, the less stable DHI being generally more toxic than DHICA to melanoma cells and nonmelanocytic cells. Moreover, the observed cytotoxic effects increased with the time of incubation and were markedly reduced by the addition of catalase to the medium, suggesting that they were probably due to the generation of reactive oxygen species (particularly H2O2) during the autoxidation of the melanin precursors outside the cells. To circumvent this problem, we then tested the diacetylated derivatives of DHI and DHICA (DAI and DAICA) which are sufficiently stable until taken up into the cells whereupon they may be converted by endogenous esterases back to the parent indoles. Although DAI proved to be cytotoxic for nonmelanocytic cells, it had no detectable activity on melanoma cells, whereas DAICA showed no effect on any of the cells examined. These results, when combined with other studies, point to a reconsideration of the inherent cytotoxicity of the 5,6-dihydroxyindoles, as well as DOPA, to melanin producing cells.

[1]  J. Pawelek,et al.  Dopachrome conversion: a possible control point in melanin biosynthesis. , 1980, The Journal of investigative dermatology.

[2]  V. Hearing,et al.  Enzymatic control of pigmentation in mammals , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  R. Spritz,et al.  Mutational mapping of the catalytic activities of human tyrosinase. , 1992, The Journal of biological chemistry.

[4]  A. Napolitano,et al.  Copolymerisation of 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid in melanogenesis: Isolation of a cross-coupling product , 1993 .

[5]  Y. Mishima A post melanosomal era: control of melanogenesis and melanoma growth. , 2008, Pigment cell research.

[6]  K. Steel,et al.  TRP-2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor. , 1992, Development.

[7]  V. Hearing,et al.  JB/MS murine melanoma: A new model for studies on the modulation of differentiation and of tumorigenic and metastatic potential , 1988, International journal of cancer.

[8]  P. Parsons Modification of dopa toxicity in human tumour cells. , 1985, Biochemical pharmacology.

[9]  S. Passi,et al.  Mechanism of antitumoral activity of catechols in culture. , 1987, Biochemical pharmacology.

[10]  J. Pawelek,et al.  5,6-Dihydroxyindole is a melanin precursor showing potent cytotoxicity , 1978, Nature.

[11]  J. Pawelek,et al.  Mammalian tyrosinase catalyzes three reactions in the biosynthesis of melanin. , 1982, Science.

[12]  F. Solano,et al.  Regulation of mammalian melanogenesis. II: The role of metal cations. , 1990, Biochimica et biophysica acta.

[13]  J. Pawelek,et al.  New regulators of melanin biosynthesis and the autodestruction of melanoma cells , 1980, Nature.

[14]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[15]  P. Riley,et al.  Melanogenesis: a realistic target for antimelanoma therapy? , 1991, European journal of cancer.

[16]  I. Jackson,et al.  Light is a dominant mouse mutation resulting in premature cell death , 1992, Nature Genetics.

[17]  K. Fujita,et al.  The mechanism of toxicity of 5-S-cysteinyldopa to tumour cells. Hydrogen peroxide as a mediator of cytotoxicity. , 1983, Biochemical pharmacology.

[18]  A. Bonfigli,et al.  5,6-Dihydroxyindole oxidation by mammalian, mushroom and amphibian tyrosinase preparations. , 1985, Biochimica et biophysica acta.

[19]  C. Garbe,et al.  A fluorometric rapid microassay to identify anti‐proliferative compounds for human melanoma cells in vitro , 1991, Melanoma research.

[20]  V. Hearing,et al.  Tyrosinases from two different loci are expressed by normal and by transformed melanocytes. , 1991, The Journal of biological chemistry.

[21]  E. Rosengren,et al.  Melanin-related biochemistry of IGR 1 human melanoma cells. , 1991, Melanoma research.

[22]  F. Solano,et al.  Comparative action of dopachrome tautomerase and metal ions on the rearrangement of dopachrome. , 1991, Biochimica et biophysica acta.

[23]  M. Wick,et al.  L-dopa: selective toxicity for melanoma cells in vitro. , 1977, Science.

[24]  P. Hochstein,et al.  THE CYTOTOXICITY OF MELANIN PRECURSORS * , 1963 .

[25]  V. Hearing,et al.  5,6-Dihydroxyindole-2-carboxylic acid is incorporated in mammalian melanin. , 1992, The Biochemical journal.

[26]  T. Broadhurst,et al.  The chemistry of the melanins. Part V. The autoxidation of 5 : 6-dihydroxyindoles , 1954 .

[27]  F. Vogel,et al.  The toxicity of melanin precursors. , 1978, The Journal of investigative dermatology.

[28]  R. Minnis,et al.  The syntheses of 5,6-dihydroxyindole and some of its derivatives , 1965 .

[29]  F. Solano,et al.  Regulation of mammalian melanogenesis. I: Partial purification and characterization of a dopachrome converting factor: dopachrome tautomerase. , 1990, Biochimica et biophysica acta.

[30]  S. Orlow,et al.  Synthesis and characterization of melanins from dihydroxyindole-2-carboxylic acid and dihydroxyindole. , 1992, Pigment cell research.

[31]  M. Wick An experimental approach to the chemotherapy of melanoma. , 1980, The Journal of investigative dermatology.